keyword
MENU ▼
Read by QxMD icon Read
search

Aromatase

keyword
https://www.readbyqxmd.com/read/29356364/the-effect-of-hormone-manipulations-on-sex-ratios-varies-with-environmental-conditions-in-a-turtle-with-temperature-dependent-sex-determination
#1
Daniel A Warner, Timothy S Mitchell, Brooke L Bodensteiner, Fredric J Janzen
Exogenous application of steroids and related substances to eggs affects offspring sex ratios in species with temperature-dependent sex determination (TSD). Laboratory studies demonstrate that this effect is most pronounced near the constant temperature that produces 1:1 sex ratios (i.e., pivotal temperature). However, the impact of such chemicals on sex determination under natural nest temperatures (which fluctuate daily) is unknown, but could provide insight into the relative contributions of these two factors under natural conditions...
April 2017: Journal of Experimental Zoology. Part A, Ecological and Integrative Physiology
https://www.readbyqxmd.com/read/29354686/e2112-randomized-phase-iii-trial-of-endocrine-therapy-plus-entinostat-placebo-in-patients-with-hormone-receptor-positive-advanced-breast-cancer
#2
REVIEW
Sri Lakshmi Hyndavi Yeruva, Fengmin Zhao, Kathy D Miller, Amye J Tevaarwerk, Lynne I Wagner, Robert J Gray, Joseph A Sparano, Roisin M Connolly
Endocrine therapies are effective in the treatment of hormone receptor (HR)-positive breast cancer, however, de novo or acquired treatment resistance is a significant clinical problem. A potential mechanism of resistance involves changes in gene expression secondary to epigenetic modifications, which might be reversed with the use of histone deacetylase (HDAC) inhibitors such as entinostat. The ENCORE 301 phase II randomized, placebo-controlled study demonstrated a significant improvement in progression-free survival (PFS) and overall survival (OS), with the addition of entinostat to exemestane in patients with HR-positive advanced breast cancer with disease progression after prior non-steroidal aromatase inhibitor (AI)...
2018: NPJ Breast Cancer
https://www.readbyqxmd.com/read/29353145/extremely-low-frequency-electromagnetic-field-emf-generates-alterations-in-the-synthesis-and-secretion-of-oestradiol-17%C3%AE-e2-in-uterine-tissues-an-in%C3%A2-vitro-study
#3
Anna Koziorowska, Ewa Monika Waszkiewicz, Maria Romerowicz-Misielak, Kamila Zglejc-Waszak, Anita Franczak
An electromagnetic field (EMF) of extremely low frequency may affect physiological processes in mammals. The aim of the present study was to determine the effect of an EMF on the synthesis and secretion of oestradiol-17β (E2) in the porcine uterus. Endometrial and myometrial slices were harvested on days 12-13 of the oestrous cycle and exposed in vitro to an EMF (50 and 120 Hz, 8 mT) for 2 and 4 h in the presence or absence of progesterone (P4). Subsequently, the incubation media were used to determine the concentration of E2 with RIA...
January 9, 2018: Theriogenology
https://www.readbyqxmd.com/read/29352052/estrogen-receptor-positive-breast-cancer-exploiting-signaling-pathways-implicated-in-endocrine-resistance
#4
REVIEW
Adam M Brufsky, Maura N Dickler
Advancements in molecular profiling and endocrine therapy (ET) have led to more focused clinical attention on precision medicine. These advances have expanded our understanding of breast cancer (BC) pathogenesis and hold promising implications for the future of therapy. The estrogen receptor-α is a predominant endocrine regulatory protein in the breast and in estrogen-induced BC. Successful targeting of proteins and genes within estrogen receptor (ER) nuclear and nonnuclear pathways remains a clinical goal...
January 19, 2018: Oncologist
https://www.readbyqxmd.com/read/29350307/living-with-chronic-pain-perceptions-of-breast-cancer-survivors
#5
Ting Bao, Andrew Seidman, Qing Li, Christina Seluzicki, Victoria Blinder, Salimah H Meghani, John T Farrar, Jun J Mao
PURPOSE: Breast cancer treatments may lead to chronic pain. For some breast cancer survivors (BCS), this experience can develop into the perception of living with chronic pain. The majority of BCS are postmenopausal and have hormone receptor-positive (HR+) breast cancer requiring aromatase inhibitors (AIs). Neither the prevalence nor risk factors associated with the perception of living with chronic pain among this population are well defined. METHODS: We conducted a cross-sectional survey among postmenopausal, HR+ BCS who previously took or were currently taking AIs...
January 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29349762/advances-in-endocrine-therapy-for-postmenopausal-metastatic-breast-cancer
#6
Lisa E Flaum, William J Gradishar
A majority of breast cancers are hormone receptor (HR) positive and are responsive to various types of hormone manipulation. Endocrine therapy is the preferred first-line therapy for patients with advanced estrogen receptor (ER) positive, HER2-negative breast cancer who do not have symptomatic visceral disease. Endocrine therapy is often continued in the second- and third-line setting, with chemotherapy deferred until tumor becomes endocrine therapy refractory and/or a visceral crisis in imminent. Therapeutic options vary based on clinical presentation and include single-agent therapies such as tamoxifen, aromatase inhibitors and fulvestrant, and combination therapies options...
2018: Cancer Treatment and Research
https://www.readbyqxmd.com/read/29349758/is-dcis-overrated
#7
Joshua Feinberg, Rachel Wetstone, Dana Greenstein, Patrick Borgen
Ductal carcinoma in situ (DCIS), the noninvasive form of breast cancer (BC), comprises just over 20% of breast cancer cases diagnosed each year in the USA. Most patients are treated with local excision of the disease followed by whole breast radiation therapy. Total mastectomy is not an uncommon approach, and total mastectomy with a contralateral risk-reducing mastectomy has been on the rise in the past decade. In estrogen receptor-positive disease, patients are often offered endocrine ablative therapy with a selective estrogen receptor modulator or an aromatase inhibitor as both treatment and prevention...
2018: Cancer Treatment and Research
https://www.readbyqxmd.com/read/29349513/3d-qsar-study-of-steroidal-and-azaheterocyclic-human-aromatase-inhibitors-using-quantitative-profile-of-protein-ligand-interactions
#8
Sehan Lee, Mace G Barron
Aromatase is a member of the cytochrome P450 superfamily responsible for a key step in the biosynthesis of estrogens. As estrogens are involved in the control of important reproduction-related processes, including sexual differentiation and maturation, aromatase is a potential target for endocrine disrupting chemicals as well as breast cancer therapy. In this work, 3D-QSAR combined with quantitative profile of protein-ligand interactions was employed in the identification and characterization of critical steric and electronic features of aromatase-inhibitor complexes and the estimation of their quantitative contribution to inhibition potency...
January 18, 2018: Journal of Cheminformatics
https://www.readbyqxmd.com/read/29344249/estradiol-suppresses-phosphorylation-of-er%C3%AE-serine-167-through-upregulation-of-pp2a-in-breast-cancer-cells
#9
Takanori Hayashi, Masahiro Hikichi, Jun Yukitake, Nobuhiro Harada, Toshiaki Utsumi
Aromatase inhibitors (AIs) are effective endocrine therapeutics for postmenopausal women with estrogen receptor (ER)α-positive breast cancer. However, the efficacy of the treatment is often limited by the onset of AI resistance, owing to the phosphorylation of ERα serine 167 (Ser167). Previous studies have indicated that hyperactivation of the phosphoinositide-3 kinase/RAC serine/threonine-protein kinase signaling pathway occurs in AI-resistant breast cancer models, which coincides with elevated levels of ERα phosphorylation at Ser167...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29344106/overall-survival-and-progression-free-survival-with-endocrine-therapy-for-hormone-receptor-positive-her2-negative-advanced-breast-cancer-review
#10
REVIEW
Tomás Reinert, Carlos H Barrios
We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer. First-line was defined as treatment for endocrine therapy-naïve advanced breast cancer or advanced disease treated with endocrine therapy in the adjuvant/neoadjuvant setting. Second-line was defined as endocrine therapy for advanced breast cancer following disease progression on endocrine therapy for advanced disease...
November 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29344105/optimal-duration-of-adjuvant-endocrine-therapy-how-to-apply-the-newest-data
#11
REVIEW
Kerstin Wimmer, Stephanie Strobl, Michael Bolliger, Yelena Devyatko, Belgin Korkmaz, Ruth Exner, Florian Fitzal, Michael Gnant
Background: The benefit of 5 years of adjuvant endocrine therapy for women with hormone receptor-positive (HR+) breast cancer (BC) is beyond discussion. Nevertheless, the risk of recurrence of luminal BC persists for 15 years or more after diagnosis. Consequently, approaches of extended adjuvant therapy have been investigated in large clinical trials, with the ultimate aim of further reducing the risk of recurrence in patients with HR+ BC. Methods: A review of recently published trial data is presented to provide a solid basis for discussion...
November 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29343958/preparation-of-anastrozole-loaded-peg-pla-nanoparticles-evaluation-of-apoptotic-response-of-breast-cancer-cell-lines
#12
Yusra A Alyafee, Manal Alaamery, Shahad Bawazeer, Mansour S Almutairi, Badr Alghamdi, Nawaf Alomran, Atia Sheereen, Maha Daghestani, Salam Massadeh
Purpose: Anastrozole (ANS) is an aromatase inhibitor that is widely used as a treatment for breast cancer in postmenopausal women. Despite the wide use of ANS, it is associated with serious side effects due to uncontrolled delivery. In addition, ANS exhibits low solubility and short plasma half-life. Nanotechnology-based drug delivery has the potential to enhance the efficacy of drugs and overcome undesirable side effects. In this study, we aimed to prepare novel ANS-loaded PLA-PEG-PLA nanoparticles (ANS-NPs) and to compare the apoptotic response of MCF-7 cell line to both ANS and ANS-loaded NPs...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29343814/intrinsic-apoptotic-pathway-activation-increases-response-to-anti-estrogens-in-luminal-breast-cancers
#13
Michelle M Williams, Linus Lee, Thomas Werfel, Meghan M Morrison Joly, Donna J Hicks, Bushra Rahman, David Elion, Courtney McKernan, Violeta Sanchez, Monica V Estrada, Suleiman Massarweh, Richard Elledge, Craig Duvall, Rebecca S Cook
Estrogen receptor-α positive (ERα+) breast cancer accounts for approximately 70-80% of the nearly 25,0000 new cases of breast cancer diagnosed in the US each year. Endocrine-targeted therapies (those that block ERα activity) serve as the first line of treatment in most cases. Despite the proven benefit of endocrine therapies, however, ERα+ breast tumors can develop resistance to endocrine therapy, causing disease progression or relapse, particularly in the metastatic setting. Anti-apoptotic Bcl-2 family proteins enhance breast tumor cell survival, often promoting resistance to targeted therapies, including endocrine therapies...
January 17, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29339527/diminished-androgen-and-estrogen-receptors-and-aromatase-levels-in-hypogonadal-diabetic-men-reversal-with-testosterone
#14
Husam Ghanim, Sandeep Dhindsa, Sanaa Abuaysheh, Manav Batra, Nitesh Kuhadiya, Antoine Makdissi, Ajay Chaudhuri, Paresh Dandona
AIMS: One third of males with type 2 diabetes have hypogonadism, characterized by low total and free testosterone concentrations. We hypothesized that this condition is associated with a compensatory increase in the expression of androgen receptors (AR) and that testosterone replacement reverses these changes. We also measured estrogen receptor and aromatase expression. MATERIALS AND METHODS: This is a randomized double-blind placebo controlled trial. 32 hypogonadal and 32 eugonadal men with type 2 diabetes were recruited...
January 16, 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29338443/barriers-to-acupuncture-use-among-breast-cancer-survivors-a-cross-sectional-analysis
#15
Ting Bao, Qing Li, Janice L DeRito, Christina Seluzicki, Eun-Ok Im, Jun Mao
INTRODUCTION: Increasing evidence suggests that acupuncture may be helpful to manage common symptoms and treatment side effects among breast cancer (BC) survivors. Acupuncture usage among BC survivors remains low with little known about the barriers to its utilization. We evaluated perceived barriers to acupuncture use among BC survivors and explored the sociodemographic variations of such barriers. METHODS: We conducted a cross-sectional analysis at an urban academic cancer center on 593 postmenopausal women with a history of stage I-III hormone receptor-positive BC who were taking or had taken an aromatase inhibitor...
January 1, 2018: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/29337392/oral-health-related-concerns-behavior-and-communication-with-health-care-providers-of-patients-with-breast-cancer-impact-of-different-treatments
#16
L Susan Taichman, Catherine H Van Poznak, Marita R Inglehart
AIM: The objectives are to compare responses of breast cancer (BCa) treatment groups (chemotherapy, tamoxifen, and aromatase inhibitors (AIs) to each other and a control regarding (a) subjective oral health, (b) oral health-related behaviors, (c) oral health-related concerns, and (d) communication with health care providers. METHODS: Survey data were collected from 140 postmenopausal BCa patients and 41 healthy postmenopausal control respondents. RESULTS: BCa patients reported on average more frequent mouth sores/mucositis (5-point scale with 1 = never: 1...
January 16, 2018: Special Care in Dentistry
https://www.readbyqxmd.com/read/29336269/design-synthesis-and-biological-evaluation-of-new-azole-derivatives-as-potent-aromatase-inhibitors-with-potential-effects-against-breast-cancer
#17
Farzin Hadizadeh, Fatemeh Kalalinia, Mohammad Jouya, Alireza Khorsand Komachal, Aboutourabzadeh Seyed Mohammad, Gholamreza Karimi, Javad Behravan, Khalil Abnous, Leila Etemad, Hossein Kamali
PURPOSE: Some aromatase inhibitors are FDA-approved agents as first-line therapy in the treatment of endocrine-responsive breast cancer. In this study, we aimed to develop new azole derivatives with higher specificity and potency. METHODS: New aromatase inhibitors were designed by Molecular Operating Environment (MOE) software and synthesized in a one-step SN2 reaction. These compounds were characterized by melting point, 1H- and 13C-NMR, elemental analysis and mass spectra...
January 15, 2018: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29334747/-drug-induced-tendon-injury
#18
Štefan Alušík, Zoltán Paluch
Tendon injury belongs to the less known side effects of some drugs, reported until recently only for glucocorticoids and fluoroquinolones. To date, some other classes of drugs such as statins, aromatase inhibitors, anabolic steroids, potentially causing tendon injury, have been added to the list. The authors discuss the most common clinical presentations, diagnosis, and management as well as latest experimental data regarding this issue. The most often, the Achilles tendon is affected, however, nearly every tendon of the entire body may be affected...
2018: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29329697/ageing-perceptions-and-non-adherence-to-aromatase-inhibitors-among-breast-cancer-survivors
#19
Moriah J Brier, Dianne L Chambless, Jinbo Chen, Jun J Mao
PURPOSE: Aromatase inhibitors (AIs) are a potentially life-saving treatment for breast cancer survivors, yet poor adherence to treatment is a prevalent problem. A common adverse effect of AI treatment is arthralgia, which is identified by survivors as a major reason for treatment discontinuation. Women who experience arthralgia on AIs often report feeling they have aged rapidly while on the treatment. In the present study, we examined whether arthralgia-associated ageing perceptions predicted non-adherence...
January 9, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29329467/low-aromatase-activity-and-estradiol-sex-hormone-binding-globulin-ratio-are-associated-with-total-hip-bone-mineral-density-and-the-presence-of-osteoporosis-a-study-in-chinese-postmenopausal-women
#20
Hai-Juan Liu, Jun Yan, Yan Li, Fang-Yuan Zhou, Xu-Dong Su, Hui-Jing Fan, Jie Bai, Guang-Zhen Zhang
Several groups have reported the important role of estradiol (E2) and testosterone (T) in postmenopausal osteoporosis (PMOP). Because aromatase catalyzes the conversion of T to E2, the purpose of this study was to determine the influence of aromatase activity on the bone mineral density (BMD) in postmenopausal women. A total of 344 postmenopausal women were selected for this study. Serum E2, T, sex hormone-binding globulin (SHBG), calcium (Ca), alkaline phosphatase (ALP), C-terminal telopeptide of type I collagen (CTX), and procollagen type I amino-terminal propeptide (PINP) were examined...
January 2018: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
keyword
keyword
42287
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"